Biosimilars: therapeutic benefits and opportunities for savings

Schermata 2018-07-03 alle 19.40.08Maxer continues its collaboration with the IQVIA Italia Study Centre by editing the text of Farmaci biologici e biosimilari: scenari terapeutici e stima del risparmio per il Sistema Sanitario italiano.

The essay analyses the evolution of the therapeutic scenarios following up the patent expiring of many originator drugs and its pharmacoeconomic implications, highlighting that the risk-benefit ratio of the biosimilars coincides with the correspondent originator.

Among the five largest European countries, Italy is placed in a medium-high position in the ranking on the penetration of biosimilars, very high in some cases (epoetin, growth hormone and G-CFS), still limited in others.

For more information see: